Edition:
United Kingdom

Erytech Reports Results Of Phase 2b Study Of Eryaspase For The Treatment Of AML


Friday, 8 Dec 2017 

Dec 8 (Reuters) - ERYTECH PHARMA SA ::ERYTECH REPORTS TOP-LINE RESULTS OF PHASE 2B STUDY OF ERYASPASE FOR THE TREATMENT OF AML.STUDY DID NOT MEET ITS PRIMARY ENDPOINT OF OVERALL SURVIVAL (OS).OS HAZARD RATIO (HR) WAS 1.06 (95% CI; 0.70, 1.61).WHEN ADJUSTING FOR MINOR IMBALANCES IN MAIN PROGNOSTIC FACTORS AT BASELINE OS HR WAS 0.98 (95% CI; 0.64, 1.50).MEDIAN NUMBER OF MONTHS ON TREATMENT WAS LESS THEN 2 MONTHS IN BOTH TREATMENT ARMS.